Loading clinical trials...

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | Clinical Trials | Clareo Health

RECRUITINGPHASE2

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Effectiveness and Safety of Camrelizumab Combined With Concurrent Chemoradiotherapy for FIGO IB2-IIIB Cervical Cancer: A Single-center, Single-arm, Open-phase II Clinical Study

NCT05311566•Lei Li

View on ClinicalTrials.gov

Summary

This study is a single-center, single-arm, open-phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with concurrent chemoradiotherapy for early and locally advanced cervical cancer, i.e., FIGO 2018 IB2-IIIB cervical cancer. Eligible subjects will be given cisplatin and radiotherapy, for 6-8 weeks, camrelizumab repeated every 14 days until disease progression, toxicity intolerance, or other reasons specified in the protocol. Subjects who finished treatment entered the safety follow-up or survival follow-up.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Histologically confirmed cervical adenocarcinoma, cervical squamous cell carcinoma, or cervical adenosquamous carcinoma and FIGO2018 IB2 to IIIB；
•2. Have not received radiotherapy, chemoradiotherapy or other'system therapy for,cervical,cancer in the past.
•3. With measurable tumor lesions (meet RECIST 1.1 standard).
•4. Age≥18 years old when signing the informed consent, female.
•5. ECOG PS: 0-2 points.
•6. Expected survival time \> 6 months.
•7. According with lab testing criteria in the protocol.
•8. Ability and willingness to comply with research and follow-up procedures.
•9. Females of childbearing potential must agree to use adequate contraception throughout the study period and for 6 months after the end of treatment.
•10. The patients voluntarily joined the clinical study and signed the informed consent, with good compliance and follow-up.

Exclusion Criteria

•1. Have previously received an anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, or anti-CTLA-4 antibody (or any other antibody that acts on T cell costimulation or checkpoint pathways);
•2. Have a clear history of allergies, and may have potential allergies or intolerances to the study drug and its similar biological agents.
•3. Participated in clinical trials of other antitumor drugs within 4 weeks before the first dose, or planned to receive live attenuated vaccines within 4 weeks before the first dose or during the study.
•4. Other malignant tumors have occurred within 5 years (except for adequately treated cutaneous squamous cell carcinoma or controlled cutaneous basal cell carcinoma).
•5. Use immunosuppressive medications, excluding nasal and inhaled corticosteroids or physiologic doses of systemic steroids (no more than 10 mg/day prednisolone or other corticosteroids at equivalent doses),within 14 days of first use of camrelizumab.
•6. Symptomatic advanced patients with visceral dissemination who are at short-term risk of life-threatening complications (including uncontrolled massive exudates \[thoracic, pericardium, abdominal\], pulmonary lymphangitis and more than 30% patients with liver involvement).
•7. Presence or history of any active autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or asthma in childhood have been completely relieved, no need for any after adulthood Asthma patients who need bronchodilator for medical intervention can not be included).
•8. Subjects with grade II or higher myocardial ischemia or myocardial infarction, and poorly controlled arrhythmias (including QTc interval ≥450ms in men and ≥470ms in women). According to the New York Heart Association standard, Subjects with grade III-IV cardiac insufficiency, or echocardiography showed left ventricular ejection fraction (LVEF) \<50%; myocardial infarction occurred within 6 months before enrollment, and New York Heart Association grade II or above cardiac function Failure, uncontrolled angina, uncontrolled severe ventricular arrhythmia, clinically significant pericardial disease, or electrocardiogram suggesting acute ischemia or active conduction system abnormalities.
•9. Concurrent severe infection (eg, requiring intravenous antibiotics, antifungals, or antivirals) within 4 weeks prior to first dose, or unexplained fever \>38.5°C during screening or before first dose.
•10. Subjects with a history of psychotropic substance abuse and unable to quit or with mental disorders.
+4 more criteria

Locations (1)

Lei Li

Beijing, Beijing Municipality, China

Key Dates

Start Date

March 27, 2022

Primary Completion Date

March 27, 2023

Completion Date

March 27, 2026

Last Updated

April 13, 2022

Enrollment

ESTIMATED participants

Conditions

Cervical CarcinomaChemoradiotherapyAnti-programmed Cell Death Receptor 1ImmunotherapyImmune Checkpoint InhibitorSurvival OutcomesAdverse EventsEarly Stage Cervical CancerLocally Advanced Cervical Cancer

Interventions

Camrelizumab plus Concurrent chemoradiotherapy

COMBINATION_PRODUCT

Contacts

Lei Li, M.D.

CONTACT

86-139-1198-8831 lileigh@163.com

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642

Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial Carcinoma+25 more

View study

RECRUITINGPHASE1/PHASE2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972

HPV-Associated Cervical CarcinomaHPV-Related Carcinoma+15 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Inclusion Criteria

Exclusion Criteria

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

The Ohio State University (OSU) SCREEN Community Program

Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer